As an Indian-origin US politician, Vivek Ramaswamy especially shot to fame last year in his short-lived bid to be the next president of the United States. However, he ultimately pulled the plug on his campaign, joining Donald Trump’s side, which has since essentially helped him stay on the Republican leader’s good side.
In addition to the fallen presidential bid in 2024, Ramaswamy has since been cut off from DOGE as well. But all’s good on that side of the table, as Trump has also endorsed him as Ohio’s governor.
One would presume that most of his fortune and fame would be attributed to his political career. If you’re one of the people holding on to that belief, it’s time you dig in deeper into Vivek Ramaswamy’s professional origins in America. He is currently running to become the governor of Ohio. Although the gubernatorial polls will take place in November 2026, the Indian-origin Republican is again climbed trends over a significant surge in his net worth. He has his old pharmaceutical company, Roivant Sciences, to thank for it.
A spokesperson for the Indian-origin biotech entrepreneur has since confirmed that the Forbes figures are “broadly correct.”
Vivek Ramaswamy net worth
According to Forbes’ real-time net worth listings, Ramaswamy is worth about $1.8 billion today. This sudden boost marks and 80% rise in just nine months, with all of its happening during his Ohio gubernatorial campaign trail. His current net worth appears to have nearly doubled from what the previous $1 billion estimation in March. At the time, he barely made Forbes’ World Billionaires List.
Vivek Ramaswamy’s governor campaign funds
On the political side of things, Ramaswamy’s gubernatorial campaign had raised $9.7 million through July end, according to the latest reports filed with Ohio’s secretary of state. On the flip side, his Democratic rival, Amy Acton, has raised a considerably lesser funds estimated at $1.4 million.
Vivek Ramaswamy pulled out all the stops for his last year’s presidential bid, spending $26 million from his own pocket to fund the race. However, a starkly contrasting picture has emerged this time. For his gubernatorial election, he has merely loaned his campaign about $200,000, as opposed to the millions he unloaded on a personal level.
Vivek Ramaswamy assets and fortune
The Ramaswamy spokesperson also confirmed that Ohio gubernatorial candidate owned a stake in the startup called Chapter, which he co-founded in 2020. Earlier this year, Bloomberg reported that the firm raised $75 million in Series D funding at $1.5 billion valuation.
Moreover, a person sharing connections with the company highlighted that Vivek Ramaswamy’s stake in it is worth about $100 million or 6.7%. as per Forbes.
Another rather smaller portion of his fortune is attributed to the “anti-woke: investment firm Strive Asset Management, which he founded in 2022. Its banner has since transformed into that of a Bitcoin treasury company.
Following that transition, the company merged with Asset Entities in September, with another intended merger announced for a ten-day later date. Beyond the ups-and-downs, Ramaswamy’s estimated stake in the company was $150 billion.
Majority of Vivek Ramaswamy’s net worth pouring in from…
Roivant Sciences.
Vivek Ramaswamy founded the company in 2014 after leaving his job at the hedge fund QVT, where he specialised in pharma investments. In the first seven years of his job, he earned $7 million and made partner. As the hedge fund backed him, he started Roivant to make a fortune off drugs that had been abandoned by pharma giants.
A year down the lie, Roivant’s spinoff called Axovant went public at a $3 billion valuation. Nonetheless, Axovant’s share price slumped with the drug trials failing in 2017. While he still continued to hold at least some Axovant stock directly, he did get rid of part of his stake in Roivant, allowing him to declare capital gains of around $37 million on his 2015 tax returns.
In 2019, the company sold five of its subsidiaries, along with 10% of the company at a $9 billion valuation to Japan’s Sumitomo for $9 billion. Subsequently, Ramaswamy boasted over $170 million in capital gains on his 2020 tax returns.
In 2021, he switched the CEO role to chairman at Roivant. With his presidential bid gaining momentum, Ramaswamy left the company board. And yet, since he owned tens of millions of shares, Roivant’s sale of another spinoff called Telavant to a Swiss pharma company for $7.1 billion helped expand the billionaire’s fortune.
With Ramaswamy’s stake in Roivant being 49 million shares, it’s worth $1 billion on its own. These soaring numbers are attributed to another Roivant subsidiary’s positive results due to brepocitinib trial. The drug targets dematomyositis, which leads to skin lesions and muscle weakness. As a result, the company’s overall stock jumped, hitting 33% since the announcement of the positive rise and 72% since the start of 2025. According to Forbes, his stock options are also adding $210 million to his net worth.
